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Background: MicroRNAs (miRNAs) represent new and potentially informative diagnostic targets for disease detection
and prognosis. However, little work exists documenting the effect of TRIzol, a common viral inactivation and nucleic acid
extraction reagent, on miRNA purification. Here, we developed an optimized protocol for miRNA extraction from plasma
samples by evaluating five different RNA extraction kits, TRIzol phase separation, purification additives, and initial plasma
sample volume. This method was then used for downstream profiling of plasma miRNAs found in archived samples
from one nonhuman primate (NHP) experimentally challenged with Ebola virus by the aerosol route.
Results: Comparison of real-time RT-PCR results for spiked-in and endogenous miRNA sequences determined
extraction efficiencies from five different RNA purification kits. These experiments showed that 50 μL plasma processed
using the QIAGEN miRNeasy Mini Kit with 5 μg of glycogen as a co-precipitant yielded the highest recovery of
endogenous miRNAs. Using this optimized protocol, miRNAs from archived plasma samples of one rhesus macaque
challenged with aerosolized Ebola virus was profiled using a targeted real-time PCR array. A total of 519 of the
752 unique miRNAs assayed were present in the plasma samples at day 0 and day 7 (time of death) post-exposure.
Statistical analyses revealed 25 sequences significantly up- or down-regulated between day 0 and day 7 post infection,
validating the utility of the extraction method for plasma miRNA profiling.
Conclusions: This study contributes to the knowledgebase of circulating miRNA extraction methods and expands
on the potential applications of cell-free miRNA profiling for diagnostics and pathogenesis studies. Specifically,
we optimized an extraction protocol for miRNAs from TRIzol-inactivated plasma samples that can be used for
highly pathogenic viruses.
Keywords: microRNA, TRIzol, Ebola virus, RNA extraction, Plasma, Biomarker, RT-PCR, Nonhuman primateBackground
MicroRNA (miRNA) profiling from plasma or serum is
emerging as a minimally invasive source of disease-
specific biomarker signatures (reviewed in [1]). Unlike
other nucleic acids, circulating miRNAs are resistant to
degradation [2-4] and can be differentially expressed ac-
cording to disease state (reviewed in [5,6]). Since the
relatively low numbers of miRNAs may simultaneously
regulate disparate gene networks [7], miRNA patterns
can be easier to analyze than global gene signatures.
However, accurately identifying circulating miRNA dis-
ease biomarkers is highly dependent on pre-analytical
variables such as sample type and collection, processing,* Correspondence: timothy.d.minogue.civ@mail.mil
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For instance, recent studies have demonstrated that
standard (platelet-replete) plasma and hemolysis can
mask true disease biomarkers through elevated blood
cell-derived miRNA levels [8-11].
Characterizing host-encoded miRNAs differentially ob-
served following exposure to highly infectious category
A pathogens such as Ebola virus, Lassa fever virus, or
Bacillus anthracis could be used to prevent disease
transmission and improve patient outcomes. However,
biomarker discovery from these agents is complicated by
the limited number of animal studies available and by
highly restricted access to these samples. In addition,
these pathogens must be inactivated by radiological,
thermal, or chemical means before removal from biocon-
tainment suites [12]. Of these methods, chemical inactiva-
tion with a guanidinium-phenol-based solution such asis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Individual endogenous miRNAs assayed using RT-
PCR
MicroRNAa Blood cell-derivedb Cq from [8]c
hsa-miR-451a Yes - RBC [11] 22.5
hsa-miR-16-5p Yes - RBC [11] 23.2
hsa-miR-93-5p No 27.2
hsa-miR-23a-3p Yes – platelet [22] 27.9
hsa-miR-423-3p Yes – platelet [22] 30.9
hsa-miR-103a-3p Yes – platelet [22] 28.6
hsa-miR-205-5p No 34
amiRBase release 21 nomenclature.
bBased on current literature.cCq values obtained from 200 μL plasma assayed
using the Exiqon Ready-to-Use PCR Human panel I V1.M. Values given are for
platelet-poor plasma samples.
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ruses as it works immediately, does not require specialized
equipment, and is compatible with multiple tissue types
[13]. TRIzol is also routinely used for RNA isolation from
clinical samples with alcohol precipitation, but overnight
incubation and extended centrifugation are recommended
to enhance miRNA yield [14]. More rapid column-based
purification kits evolved from this method, and historically
most miRNA studies have used either the Ambion mir-
Vana or QIAGEN miRNeasy kits (reviewed in [6]).
Samples can also be lysed with TRIzol and purified via
spin column in a hybrid approach [3]. However, incon-
sistencies in miRNA yield and sample-to-sample variance,
dependent on RNA extraction, have been reported
[10,15,16]. Also, at low cell densities, miRNA isolation
using TRIzol significantly decreased the recovery of se-
quences with stable secondary structure and low GC con-
tent [17]. Consequently, extraction methodologies must
be optimized for each sample type and application [18].
In this study, we initially evaluated five commercially
available spin column-based RNA isolation kits for puri-
fication of TRIzol-inactivated nonhuman primate (NHP)
plasma samples. RNA recovery was assessed using RT-
PCR assays targeting synthetic spike-in RNA sequences
as well as selected endogenous miRNAs. Glycogen and
linear acrylamide were investigated as nucleic acid co-
precipitants since RNA yields from cell-free samples
such as plasma are low [7]. Minimum plasma volumes
were determined for miRNome expression profiling, and
optimized extraction parameters were used in a pilot
study utilizing archived plasma samples from one NHP
infected with Ebola virus.
Results
Healthy nonhuman primate (NHP) plasma sample
characterization
Previous studies have shown that blood cell contamin-
ation can artificially inflate miRNA expression levels
[8-11,15,19], so plasma samples must be tested for
hemolysis. For the RNA extraction protocols tested
here, we used a pooled plasma sample from three
healthy NHPs. Two successive centrifugation steps re-
moved the majority of platelets in the samples; a
hematology analyzer measured the platelet count of twice-
centrifuged plasma as 6,930 cells/μL, and hemoglobin
content at 0.05 g/L. These values indicate that the plasma
sample was platelet-poor and not hemolyzed. Lack of
hemolysis-dependent miRNA elevation suggested minimal
blood cell contamination and negligible impact on miRNA
expression changes.
QIAGEN kits yielded best miRNA recovery
Selective elution of RNA < 200 nt (small RNA enrichment)
can reduce miRNA recovery and introduce experimentalbias [20], so manufacturers’ protocols were modified for
optimal isolation of total RNA (Additional file 1: Sup-
plementary methods). Since extracted RNA could not
be measured spectrophotometrically or with an Agilent
BioAnalyzer (data not shown), kit performance was
evaluated using individual miRCURY LNA real-time
PCR assays (Exiqon, Inc.). We used three Exiqon syn-
thetic spike-in sequences, designed to mimic miRNAs
with short sequence lengths and GC content ranging
from 43-50% [21], for preliminary evaluation of miRNA
recovery. In addition, we chose seven endogenous miRNA
sequences based on previously published data shown in
Table 1. Specifically, these sequences showed consistent
abundance and persistence in plasma samples. Both blood
cell-derived [11,22] and circulating species were selected
to assess miRNA recovery.
Monitoring extraction of these seven endogenous and
three spike-in sequences extracted from 10 separate ali-
quots of the pooled plasma sample showed increased
RNA yields from the QIAGEN RNeasy and miRNeasy
kits compared to the other three protocols tested
(Table 2). On average, these kits enabled miRNA detec-
tion at 7.4, 2.8, and 2.0 cycles before the Ambion, Exi-
qon, and Zymo kits, respectively (linear mixed effects
model, p < 0.0001). RNA extracted using the QIAGEN
kits also resulted in detection of the seven miRNA se-
quences in 10 of 10 technical replicates. In contrast, the
other kits demonstrated varying recoveries of lower-
abundance miRNA species. Of note, the Ambion mirVana
kit resulted in UniSp5 detection in 3 of 10 technical repli-
cates, and hsa-miR-205-5p was not detected in any plasma
samples. Thus, we downselected to the QIAGEN RNeasy
and miRNeasy kits for subsequent testing.
Phase separation decreases sample-to-sample variance
Separation of the aqueous phase after TRIzol lysis may
lead to reduction in miRNA yields due to extra sample
manipulation and possible sample loss. Since the Zymo
Direct-zol kit does not require phase separation prior to
Table 2 MiRNA recovery by kit, presented as average Cq ± SD (n = 10)










UniSp2 28.6 ± 0.3 24.9 ± 0.4 21.8 ± 0.4 21.5 ± 0.3 23.7 ± 0.5
UniSp4 34.8 ± 0.9 31.9 ± 0.6 28.9 ± 0.8 28.7 ± 0.8 30.9 ± 0.4
UniSp5 33.7 ± 6.0(3) 36.4 ± 0.4(7) 34.7 ± 1.4 34.1 ± 2.0 38.3 ± 3.6(8)
hsa-miR-451a 30.6 ± 0.4 26.8 ± 0.5 23.7 ± 0.3 23.6 ± 0.4 25.2 ± 0.5
hsa-miR-16-5p 31.3 ± 0.4 27.6 ± 0.5 24.7 ± 0.4 24.8 ± 0.5 26.6 ± 0.5
hsa-miR-93-5p 34.6 ± 0.5 31.0 ± 0.5 28.4 ± 0.4 28.5 ± 0.4 30.3 ± 0.5
hsa-miR-23a-3p 35.8 ± 0.6 31.9 ± 0.4 29.6 ± 0.4 29.5 ± 0.5 31.3 ± 0.6
hsa-miR-423-3p 40.6 ± 4.7(4) 33.1 ± 0.8 31.1 ± 0.4 31.1 ± 0.4 33.2 ± 0.4
hsa-miR-103a-3p 38.9 ± 1.5(8) 33.9 ± 0.5 31.5 ± 0.3 31.5 ± 0.5 32.2 ± 1.2
hsa-miR-205-5p NA(0) 36.5 ± 0.5(9) 35.5 ± 0.6 35.6 ± 0.6 38.1 ± 1.9
Numbers in parentheses represent numbers of samples where miRNA was recovered, if less than 10 of 10 technical replicates. These entries are in bold
for convenience.
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(monophase) plasma-TRIzol lysate as input to the spin
columns. A comparison of the recovery of the spike-in
sequences UniSp2, UniSp4, and UniSp5 showed no sta-
tistically significant differences in the means obtained
for the two QIAGEN kits (Figure 1). However, UniSp5
was not detected in 1 of 6 monophase samples obtained
with the RNeasy kit. Also, we observed a trend of lower
measurement variability with extractions using the aque-
ous phase (Figure 1, individual data points), so subse-
quent tests used this as input to the two QIAGEN kits.Figure 1 Effect of phase separation on miRNA recovery using
QIAGEN spin column-based purification kits. The recovery of three
different amounts of spike-in sequences (UniSp2, circles; UniSp4,
squares; UniSp5, triangles) was compared by real-time RT-PCR for
unspun TRIzol-plasma lysate (monophase) and TRIzol-plasma aqueous
phase as kit inputs. Boxplots represent aggregated Cq values from the
three spike-ins, with whiskers at the minimum and maximum
values, and the line drawn at the median. Individual datapoints are
included to show spread (n = 6 for each sequence; total n = 18).
While the difference in yields was not statistically significant, using
the aqueous phase showed a trend of decreased
sample-to-sample variance.Addition of glycogen as co-precipitant improves miRNA
recovery
Glycogen or linear acrylamide is a common co-precipitant
for enhanced RNA recovery [3,16,23,24]. Preliminary test-
ing using synthetic spike-in sequences showed that the
addition of these carriers improved short RNA recovery
(Figure 2A). Linear acrylamide decreased the mean Cq by
1.2 using the RNeasy kit (linear mixed effects model, p <
0.0001) but did not improve Cq values relative to the no
carrier control with the miRNeasy kit. Glycogen addition
improved detection by 1.7 Cq earlier, on average, for both
kits (p < 0.0001). While differences between the kits were
not significant, the miRNeasy kit with glycogen showed a
trend of decreased variability. The addition of glycogen
decreased Cq for all miRNAs tested by an average of 1.3
(p < 0.0001), and appeared to reduce variability for the
higher-abundance sequences. Thus the miRNeasy kit, with
glycogen carrier, was used for further experimentation
using seven endogenous miRNAs (Figure 2B).
MiRNA extraction efficiency decreases with plasma volume
One significant limitation of studies using clinical spec-
imens (i.e., human or NHP) is restricted sample collec-
tion. Here, we evaluated miRNA recovery efficiencies
using different starting volumes of NHP plasma to de-
termine the lowest volume that could be used for
miRNA profiling. Recovery of both spike-in and endogen-
ous miRNA sequences from a range of input plasma
volumes showed significantly higher exogenous RNA
expression levels in the water-only control (0 μL plasma,
Figure 3A) compared to those obtained from 5, 10, 25, or
50 μL plasma (linear mixed effects model, p < 0.0001).
Expression levels decreased with plasma volume (p <
0.0001) for the endogenous miRNAs assayed (Figure 3B).
The water-only (no plasma) negative controls showed no
observable contamination, while all seven miRNAs were
detected from 5 μL of plasma eluted in 50 μL water after
Figure 2 MiRNA recovery with 5 μg glycogen or linear
acrylamide as a co-precipitant during RNA extraction. A. The
effect of glycogen or linear acrylamide (LA) on miRNA recovery was
determined for the RNeasy and miRNeasy kits. Boxplot whiskers
indicate minimum and maximum values, with the line drawn at the
median. Individual datapoints show the spread (n = 6 for each
sequence; total n = 18). Extraction efficiencies were compared to the
no carrier control sample, and significance was calculated using a
linear mixed effects model. **** indicates p < 0.0001, NS = not
significant. B. The impact of glycogen on endogenous miRNA recovery
was assessed using real-time RT-PCR. The error bars represent the
standard deviation from six technical replicates.
Figure 3 MiRNA recovery from decreasing amounts of plasma
input. The impact of plasma volume on the recovery of (A)
exogenous RNA sequences and (B) endogenous miRNAs was
evaluated using real-time RT-PCR. Plasma samples were diluted in
water to 50 μL and processed with the QIAGEN miRNeasy Mini Kit. In
(A), three synthetic sequences of different amounts were spiked
into the samples and measured in six technical replicates. Significance
compared to the water-only control was determined using a linear
mixed effects model, **** = p < 0.0001. Endogenous miRNAs were not
detected in any water-only controls (Cq > 40).
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showed the absence of target in 50% of the lowest abun-
dance hsa-miR-205-5p (mean Cq = 37.41) and in 10% of
hsa-miR-423-3p (mean Cq = 33.74). Consequently, sub-
sequent miRNA profiling experiments used 50 μL of
plasma.
Evaluation of miRNA extraction methodology for
miRNome profiling using archived plasma from one Ebola
virus-challenged NHP
We next evaluated the optimized miRNA extraction
protocol using archived rhesus macaque plasma samples
from one Ebola virus-infected NHP. MiRNA profilingwas conducted on two separate plasma samples from
one animal collected at day 0 and day 7 following expos-
ure to aerosolized virus. Using raw Cq values and prior
to any normalization steps, 536, 389, 251, and 174 miRNA
sequences were detected at Cq cutoffs of 40, 35, 32, and
30, respectively. These sequences were detected in at least
one timepoint and in at least one PCR technical replicate.
Further analysis confirmed the presence of 519 of the
752 unique miRNAs (for Cq < 40) included in the Exi-
qon Ready-to-Use Human panel I + II V3.R in at either
day 0 or day 7. Of these, 92 sequences were uniquely
present at time of death, while one miRNA was novel to
day 0 (data not shown). Overall, a comparison of the
miRNA profiles for both days (paired t-test using three
technical PCR replicates per timepoint) revealed 25 se-
quences significantly up- or down-regulated (p < 0.0001)
between pre-infection and time of death (Figure 4).
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quences detected (71.3% of the Exiqon panel) parallels
the percentage of rhesus macaque sequences that are
identical to human (75.5% of miRBase release 12 [25]).
As well, sequences reported to be potentially affected by
TRIzol isolation [17] were represented in our dataset
(Additional file 2: Table S1).
Discussion
Numerous pre-analytical variables in cell-free blood can
significantly impact apparent miRNA profiles. For ex-
ample, while the miRNA spectra in both plasma and
serum are highly correlated [26,27], the use of plasma
can avoid clotting-triggered release of miRNAs that can
obscure disease-specific sequences [28]. Similarly, for
plasma, EDTA is the preferred anticoagulant as heparin
can inhibit PCR [29,30] while sodium citrate can dilute
plasma and cause hemolysis [31]. Blood samples must
also be processed within 1 hour of collection [32], and
additional centrifugation is required to produce platelet-
poor plasma. Using platelet-depleted plasma substan-
tially decreases blood cell-associated miRNAs, preserves
relevant species in circulation, and reduces the variance
in expression levels [19]. However, blood cell rupture
can also inflate associated miRNA levels so hemolysis
must be checked with a hematology analyzer prior to
RNA extraction [11], or possibly after PCR by calculating
the difference between miRNAs unaffected and affected
by hemolysis (Cq(hsa-miR-23a-3p)-Cq(hsa-miR-451a))
[11,21]. Overall, these factors necessitate consistent andFigure 4 MiRNA changes in one rhesus macaque following
exposure to aerosolized Ebola virus. Plasma samples from a single
NHP challenged with aerosolized Ebola virus were processed using the
optimized miRNA extraction protocol. Individual miRNAs were
quantified using the Exiqon microRNA Ready-to-Use PCR Human panel
I + II V3.R. Twenty-five miRNA sequences (colored filled circles above
the horizontal line at p = 0.0001) were significantly altered between
virus exposure and time of death. Orange circles indicate upregulated
miRNAs, while blue circles specify downregulated sequences. A paired
t-test using three PCR technical replicates at each timepoint (day 0 and
day 7) was used to identify differentially expressed miRNAs in
these datasets.high efficiency extraction protocols for reliable profiling of
miRNAs in disease states.
Multiple kits and methodologies are currently available
for plasma miRNA isolation. However, samples contain-
ing category A pathogens must be inactivated, typically
using TRIzol LS or similar guanidinium and phenol so-
lutions, prior to removal from biosafety level (BSL)-3
and BSL-4 biocontainment suites [12,13]. While stand-
ard RNA extraction from TRIzol can improve miRNA
yield and decrease interassay variability compared to
column-based kits [10], this method is time-consuming
and highly dependent on operator skill. Instead, we
chose to optimize TRIzol-treated plasma lysate as the in-
put to five column-based RNA purification kits. Manu-
facturers’ protocols were modified where necessary to
isolate total RNA, as expression profiling using only the
small RNA fraction (<200 nt) was shown to be inferior
to using total RNA, with 65-88% apparent expression
loss after small RNA enrichment [20]. Based on RT-PCR
assays for spiked-in and endogenous sequences, the
QIAGEN RNeasy and miRNeasy kits performed best.
Both enabled miRNA detection 2.0 cycles earlier, on
average, than the closest competitor. All kit protocols fa-
cilitated quick and easy RNA isolation, but the Zymo
Direct-zol kit, which takes plasma-TRIzol lysate without
phase separation as input, took significantly less time to
complete. We tested this monophase input with the
QIAGEN RNeasy and miRNeasy kits to decrease extrac-
tion time, but observed greater variability in miRNA ex-
pression. We therefore recommend phase separation for
miRNA profiling studies.
Plasma contains very low levels of RNA, so carrier
molecules such as yeast RNA, glycogen, or linear acryl-
amide can be included to improve miRNA recovery and
extraction reproducibility [33,34]. Results here showed
that glycogen was a superior carrier, enhancing miRNA
detection ~3-fold compared to extractions with no car-
rier or with linear acrylamide. Interestingly, linear acryl-
amide did not improve RNA recovery when used with
the QIAGEN miRNeasy kit, but did increase miRNA
yield with the RNeasy kit. While the use of biologically-
derived glycogen could potentially interfere with down-
stream analyses [3], no amplification was observed using
endogenous miRNA primer sets with no reverse tran-
scriptase controls (data not shown).
We also tested the effect of decreasing the initial
plasma amount on miRNA profiling. The use of low
plasma volumes is particularly relevant in studies with
restricted human or NHP clinical samples. NHP studies
are usually limited in animal number due to ethical rea-
sons as well as the costs of care and biocontainment. Re-
peated or large volume blood collection may also
become problematic as the disease progresses. Further,
several recent studies have established that input plasma
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due to spin column clogging or polymerase inhibitor
carryover [16,35,36]. In one study, reducing plasma in-
put volume from 200 μL to 50 μL improved the detec-
tion of endogenous hsa-miR-16-5p threefold, supporting
the argument for lower sample input volumes [15]. Here,
we examined differences in plasma miRNAs for sample
volumes from 5 to 50 μL. These results showed that
even 5 μL of plasma significantly decreased recovery of
exogenous RNA. This may be attributed to RT or PCR
inhibition due to the carryover of plasma components,
as spin column clogging from such a low sample volume
is unlikely, and the low amounts of RNA recovered
argue against reagent limitation during cDNA synthesis.
Seven plasma miRNAs, spanning a range of abundances,
were detected in all sample volumes tested. However,
the identification of lower-abundance miRNAs from very
low plasma volumes may be compromised. Based on
these findings, we recommend miRNA profiling from
50 μL of plasma. Once suitable miRNA biomarkers have
been identified and validated, it may be possible to use
minimal sample volumes if miRNA abundance is not ex-
pected to be low.
As a proof of concept, we used this extraction meth-
odology with archived plasma samples from an unrelated
study of NHPs exposed to aerosolized Ebola virus [37].
We chose the LNA-based Exiqon platform because of its
demonstrated sensitivity and specificity for clinical sam-
ples with low miRNA abundance [38,39]. With a Cq cut-
off of 40, 536 (71.3%) of the 752 unique miRNA
sequences were detected in at least on PCR replicate
and in either timepoint. This number is close to the re-
ported percentage of rhesus macaque sequences that are
identical to human miRNAs, which is 75.7% (523 of 692
miRNAs recognized at the time) [25]. The number of
miRNAs detected from 50 μL plasma is also comparable
to the number of miRNAs identified from 200 μL of
starting material assayed with an older version of the
Exiqon panel [8]. Both of these results are in contrast to
a similar study using 300 μL of pre-amplified plasma,
where at most 65 miRNAs (out of 754) profiled with the
TaqMan Array Human MicroRNA A+B Cards were rec-
ognized [40].
The level of miRNA representation from the Exiqon
panels suggests that this method may circumvent TRIzol-
associated loss of certain miRNAs. This selective recovery
from using TRIzol for miRNA isolation from low numbers
of cells was reported for sequences with low GC content
and stable secondary structure, such as hsa-miR-141-3p,
-193a-3p, -301a-3p, -200a-3p, -15a-5p, -324-5p, -106b-5p,
-34a-5p, -21-5p, -20a-5p, -19b-3p, -29b-3p [17]. MiRNAs
reportedly unaffected by TRIzol extraction include those
from the let-7 family, hsa-miR-200c-3p, -29a-3p, and -25-
3p. The authors postulated that small RNAs need to becarried by longer transcripts during the precipitation step
of non-column-based TRIzol extraction. Structured, GC-
rich miRNAs likely base-pair less efficiently to these lon-
ger RNA sequences and are therefore lost during the puri-
fication process. Our method aimed to avoid biases in
miRNA recovery by adding an RNA carrier and by using
spin columns instead of liquid phase precipitation. These
findings indicate that our method, and the Exiqon panels,
are well-suited for miRNA profiling from low volumes of
frozen plasma. In a preliminary investigation using plasma
from one rhesus macaque, a comparison of the miRNAs
expressed at day 0 and day 7 post-exposure to aerosolized
Ebola virus identified 25 differentially expressed se-
quences. While the biological and statistical relevance of
these sequences is under study, the results demonstrate
that the miRNA extraction and profiling methods chosen
are suitable for potential biomarker discovery. Pending
confirmation using archived samples from the same NHP
cohort, differentially expressed miRNA sequences may be
used to construct an Ebola virus miRNA signature of
infection.
Conclusions
In this work, we present an optimized RNA extraction
protocol for TRIzol-inactivated plasma samples. We eval-
uated five commercially available spin column-based kits
for the isolation of total RNA from TRIzol-lysed nonhu-
man primate (NHP) plasma samples. The QIAGEN miR-
Neasy Mini Kit, used with the aqueous phase of 50 μL
plasma co-purified with 5 μg of glycogen, yielded the high-
est miRNA recovery. We verified this protocol using ar-
chived plasma from one rhesus macaque exposed to
aerosolized Ebola virus. Preliminary findings from two
plasma collection timepoints indicate that this method




The rhesus macaque plasma samples were archived sam-
ples not collected specifically for this study. The NHP
experiment and procedures were approved by the U.S.
Army Medical Research Institute of Infectious Diseases
(USAMRIID) Institutional Animal Care and Use Com-
mittee (IACUC) and were carried out in compliance
with the regulations outlined in the USDA Animal Wel-
fare Act (PHS Policy) and other Federal statutes and reg-
ulations relating to animals and experiments involving
animals. The facility where this research was conducted
is accredited by the Association for Assessment and Ac-
creditation of Laboratory Animal Care, International and
all animal work done adhere to the conditions specified
in the Guide for the Care and Use of Laboratory Ani-
mals [41]. Animals were given enrichment (including
Duy et al. BMC Genomics  (2015) 16:95 Page 7 of 9toys and mirrors) regularly as recommended by the
Guide for the Care and Use of Laboratory Animals. Food
was provided (commercial biscuits, fruit), and animals
were checked at least daily according to the protocol. All
efforts were made to minimize painful procedures; the
attending veterinarian was consulted regarding painful
procedures, and animals were anesthetized prior to phle-
botomy. Following the development of clinical signs, an-
imals were checked multiple times daily. When clinical
observations and scores of animals reached defined
levels based on the approved IACUC protocol (scores
based on a combination of responsiveness, recumbency,
and clinical signs), animals were euthanized by exsan-
guination following deep anesthesia and administration
of a pentobarbital-based euthanasia solution to minimize
pain and distress. All animals were housed at
USAMRIID.
Collection and processing of blood from healthy
nonhuman primates
Blood samples were obtained from three healthy male
cynomolgus monkeys housed at the USAMRIID Veter-
inary Medicine Corps. Whole blood (20 mL from each
animal) was collected into 10 mL EDTA tubes (BD Bio-
sciences, Franklin Lakes, NJ) and processed within
1 hour, as recommended in the National Cancer Insti-
tute Early Detection Research Network consensus state-
ment [32]. Blood tubes were spun in an Eppendorf
5810R centrifuge at 1,300 × g for 15 minutes at room
temperature, with no brake applied, to obtain plasma.
The upper (plasma) phase was collected to above 5 mm
of the buffy coat for each sample, and combined to pro-
duce one pooled sample for all subsequent steps.
Platelet-poor plasma was obtained by distributing the
pooled sample into clean 15 mL conical centrifuge tubes
and re-spinning at 3,220 × g for 10 minutes at room
temperature with a brake setting of 9. The supernatant
was transferred to 1.5 mL microcentrifuge tubes and
stored at -80°C until use. Plasma was analyzed for a
complete blood count with a Cell-Dyn 3700 hematology
analyzer (Abbott Laboratories, Abbott Park, IL).
Archived plasma samples from rhesus macaques chal-
lenged with aerosolized Ebola virus were acquired. Blood
samples were obtained with Vacuette K2 EDTA tubes.
Plasma was separated by centrifugation at 3,000 × g for
10 minutes, mixed with 3 volumes of TRIzol LS (Life
Technologies, Grand Island, NY) and archived at −80°C
until use. These plasma samples were not collected for
the purpose of this study.
RNA extraction from healthy nonhuman primate plasma
using TRIzol LS
All kit evaluations were performed using the same
pooled plasma sample from three healthy NHPs. Thissample was aliquoted to avoid freeze-thawing cycles. For
the initial five kit evaluation, 50 μL volumes (10 repli-
cates) of the initial pooled sample were extracted with
each kit. Subsequent tests of phase input, co-precipitant
use, and plasma volume used 6 plasma aliquots per
treatment group. For example, for RNA carrier evalu-
ation, 6 plasma aliquots were processed for each test
condition (glycogen or linear acrylamide), for a total of
12 extractions per QIAGEN kit. For each RNA extrac-
tion, 5 to 50 μL once-thawed plasma was diluted with
water to a volume of 250 μL, and 750 μL TRIzol LS was
added. The solution was vortexed and incubated at room
temperature for 5 minutes. Glycogen or linear acryl-
amide (5 μg, obtained from Life Technologies) was
added at this point for samples with co-precipitants.
Synthetic sequences (1 μL) from the RNA spike-in kit
(Exiqon, Inc., Woburn, MA) were added, followed by
150 μL of chloroform. Each tube was vortexed vigorously
for 30 seconds and allowed to sit at room temperature for
3 minutes. Phase separation was achieved by centrifuging
the sample for 12,000 × g for 15 minutes at 4°C. After cen-
trifugation, 400 μL of the aqueous phase was carefully
transferred to a new tube for spin column purification.
Total RNA purification using spin column-based kits
The following commercially available RNA purification
kits were tested in this study: mirVana miRNA Isolation
Kit (Ambion, Austin, TX), miRCURY Isolation Kit –
Biofluids (Exiqon, Inc.), RNeasy Mini Kit (QIAGEN Inc.,
Valencia, CA), miRNeasy Mini Kit (QIAGEN Inc.), and
Direct-zol RNA MiniPrep Kit (Zymo Research Corp., Ir-
vine, CA). Total RNA was purified from the aqueous
phase, with the exception of the Zymo Direct-zol kit,
which was used immediately after the addition of the
RNA spike-ins. Kit protocols were modified (Additional
file 1: Supplementary methods) to obtain total RNA, and
RNA was eluted from all columns with 50 μL molecular
biology-grade water.
Individual microRNA PCR assays
All kits used in this section were obtained from Exiqon,
Inc. Extracted RNA was reverse-transcribed with the
cDNA Synthesis Kit II using 10 μL reaction volumes
with 2 μL of input RNA. Following the manufacturer’s
protocol, cDNA was diluted 40× and mixed with the
ExiLENT SYBR Green master mix and individual micro-
RNA LNA PCR primer sets. Primer sets used were for
the synthetic miRNA spike-ins UniSp2, UniSp4, and
UniSp5, as well as for the endogenous targets hsa-miR-
16-5p, hsa-miR-23a-3p, hsa-miR-93-5p, hsa-miR-103a-
3p, hsa-miR-205-5p, hsa-miR-423-3p, and hsa-miR-451a
(Table 1). Amplifications were performed in duplicate in
clear 96-well plates on a LightCycler 480 II (Roche, San
Francisco, CA) using manufacturer-recommended cycling
Duy et al. BMC Genomics  (2015) 16:95 Page 8 of 9conditions: 95°C for 10 min, 45 cycles of 95°C for 10 s, 60°
C for 1 min with a ramping rate of 1.6°C/s, and a final
melt-curve analysis.RNA extraction and analysis of microRNA content in
Ebola virus-infected nonhuman primates
Archived plasma samples from one rhesus macaque, col-
lected at days 0 and 7 (time of death) post-challenge,
were thawed on ice. The animal was anesthetized with
6 mg/kg telazol prior to phlebotomy on both day 0 and
day 7. Blood collection on day 7 was performed ante-
mortem, after administration of telazol but before pento-
barbital. Two hundred (200) μL TRIzol-plasma lysate
(containing 50 μL plasma) was processed with 5 μg
glycogen as described for the healthy nonhuman primate
plasma samples. After phase separation, total RNA was
purified from 400 μL of the aqueous phase using the
modified miRNeasy kit protocol (Additional file 1: Sup-
plementary methods). Extracted RNA was reverse-
transcribed with the cDNA Synthesis Kit II using 8 μL
RNA for each 40 μL sample. cDNA samples were pooled
and mixed with ExiLENT SYBR Green master mix, and
10 μL of this mixture was used in each well of the
microRNA Ready-to-Use PCR Human panel I + II V3.R
(Exiqon Inc.). Three PCR technical replicates were run
for each time point, using the same cycling conditions
described above for individual miRNA assays.Data analyses
Cq values for individual assays were obtained using the
second derivative method within the integrated Roche
LightCycler 480 software version 1.5.1. A sample was
considered positive if Cq < 40, and missing Cq values
(from undetected miRNAs) were set to 45 (total number
of PCR cycles) prior to statistical testing. Analyses of
RNA extraction parameters were performed in R version
3.1.0 [42], using a linear mixed effects model with the
kit as a fixed effect.
GenEx 6 Enterprise software (MultiD Analyses AB,
Göteborg, Sweden) was used to analyze PCR panel data.
MiRNA expression levels were calculated using the
ΔΔCq method [43] with global normalization [44].
Briefly, interplate and spike-in calibrations were per-
formed, followed by removal of samples with Cq > 39.4
and miRNAs that were not detected in 5 of 6 replicates.
Global normalization of Cq values was performed by
using the mean of all samples with Cq < 36 (per day).
Relative quantities of each miRNA were calculated with
respect to the average expression level on day 0, then
data were log2 transformed and compared using a paired
t-test. The miRNA RT-PCR data used in this study is
available in the Gene Expression Omnibus database
(GSE64579).Additional files
Additional file 1: Supplementary methods. Manufacturer kit protocols
(except for the Zymo Direct-zol protocol) were modified for the isolation
of total RNA from plasma.
Additional file 2: Table S1. Normalized Cq values of microRNAs
(miRNAs) potentially affected/unaffected by TRIzol extraction from low
numbers of cells.
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